Podcast Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.” August 19, 2026
Drugs & TargetsFree FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma August 14, 2026Vol.52 No.32
Drugs & TargetsFree FDA advisory committee to vote on GRAIL’s multi-cancer detection test, Galleri August 14, 2026Vol.52 No.32
Drugs & TargetsFree FDA approves companion diagnostic supporting patients with advanced melanoma August 14, 2026Vol.52 No.32
Regulatory News FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committeeAmid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial August 07, 2026Vol.52 No.31By Jacquelyn Cobb and Paul Goldberg
Podcast Pour a Scotch, we’re talking clinical trials and prediction markets August 05, 2026Vol.52 No.31
Cancer Policy FDA’s OCE publishes three final guidances to increase clinical trial enrollment July 31, 2026Vol.52 No.30By Jacquelyn Cobb
Drugs & Targets After two CRLs, FDA advisory committee votes in favor of Replimune’s melanoma drug July 31, 2026Vol.52 No.30
